PCGF5 inhibitors are a class of chemical compounds designed to target polycomb group ring finger protein 5 (PCGF5), a member of the polycomb group (PcG) proteins. These proteins are part of the polycomb repressive complexes (PRCs), which play a crucial role in regulating gene expression through chromatin remodeling and the establishment of epigenetic silencing. PCGF5 is specifically involved in the PRC1 complex, which catalyzes the ubiquitination of histone H2A, leading to transcriptional repression of target genes. This process is essential for controlling gene expression during development, differentiation, and the maintenance of stem cell pluripotency. By inhibiting PCGF5, these compounds interfere with its role in epigenetic regulation and chromatin structure modulation, providing a means to study the impact of PRC1-mediated gene silencing on cellular processes.
The action of PCGF5 inhibitors involves blocking the protein's ability to function within the PRC1 complex, preventing it from catalyzing the ubiquitination of histones and, consequently, disrupting the repressive chromatin state it helps establish. This inhibition affects gene expression patterns, making it a useful tool for investigating how PcG proteins control developmental pathways and maintain cellular identity through epigenetic modifications. By targeting PCGF5, researchers can explore its specific role in modulating chromatin dynamics and the broader regulatory mechanisms that govern transcriptional repression. PCGF5 inhibitors are valuable for understanding the molecular mechanisms behind gene silencing, epigenetic memory, and how PcG proteins maintain stable gene expression patterns across different cell types and developmental stages. These insights help unravel the complex interplay between chromatin remodeling and gene regulation in the context of cellular differentiation and development.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $90.00 $238.00 $300.00 | ||
EZH2 inhibitor, impacting the PcG complex, can indirectly influence PCGF5 activity. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
Targets EZH2, another PcG protein; potential indirect influence on PCGF5. | ||||||
PRT4165 | 31083-55-3 | sc-507487 | 10 mg | $131.00 | ||
Inhibits PRC1 complex, of which PCGF5 is a component. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
Dual EZH1/EZH2 inhibitor, impacting broader PcG function and potentially PCGF5. | ||||||
N-[3-[[2-[[4-[[1-(2-Fluoroethyl)-3-azetidinyl]amino]-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide | 1375465-09-0 | sc-499486 | 5 mg | $340.00 | ||
Targets WDR5, associated with PcG complexes; can indirectly influence PCGF5. | ||||||
UNC0638 | 1255580-76-7 | sc-397012 | 10 mg | $315.00 | ||
Targets G9a and GLP, affecting PcG-associated pathways; potential influence on PCGF5. | ||||||
UNC 0642 | 1481677-78-4 | sc-397059 | 10 mg | $230.00 | 3 | |
Targets G9a and GLP, impacting PcG-associated functions; can indirectly influence PCGF5. | ||||||
EPZ005687 | 1396772-26-1 | sc-497734 | 2.5 mg | $380.00 | ||
EZH2-specific inhibitor; can have potential indirect effects on PCGF5 through PcG complex modulation. | ||||||